



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 June 2015
EMA/28021/2015
Press Office

Organisational matters

CHMP meeting 22-25 June 2015

The main organisational topics addressed during the June meeting related to:

- Information on EMA survey to stakeholders on Type IBs, Type IIs and PSURs (human medicines). From April 2015, the Agency is undertaking a survey on some post-authorisation centralised procedures to help to improve regulatory processes and related guidance (see [external communication on EMA website](#)). Marketing Authorisations Holders are requested to provide their feedback on Type IBs, Type IIs and PSURs procedures with opinion/notifications from 1st April to 30th September 2015 by completing the following survey: <https://www.surveymonkey.com/r/7L3S3RS>.
- Update on activities in CHMP 2015 Work Plan. Furthermore the CHMP had initial discussion for drafting a list of proposed topics for CHMP 2016 Work Plan.
- Update of CHMP D210 Assessment Report template for initial marketing authorisation applications.
- The CHMP agreed on the area of expertise for the 5th co-opted member as epidemiology.
- Discussion on outcome and follow-up items from the Strategic Review and Learning Joint CHMP and CAT Meeting under Latvian Presidency, Ljubljana, Slovenia held on 26-28 May 2015.
- The adoption of timetable to reflect that the August CHMP plenary will be replaced by a CHMP written procedure.
- Nomination of Anne-Catherine Thomas from Belgium as observer to the Central Nervous System Working Party.
- Nomination of Jiri Haman from Czech Republic as observer to the Biostatistics Working Party.

